J&J Remicade "Dear Doctor" Letter Warns Of Hepatotoxicity Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Remicade label adds warnings on hepatotoxicity and risk of infections relating to pneumonia based on post-marketing reports. FDA approves new indication for the TNF-inhibitor for treatment of ankylosing spondylitis.
You may also be interested in...
“Early Escape” Strategy In RA Trials Is One Response To Placebo Concerns, Centocor Says
One response to concerns over the use of placebo therapy in rheumatoid arthritis trials is to exercise an "early escape" strategy, Centocor Executive Director-Immunology Clinical R&D Daniel Baker said
“Early Escape” Strategy In RA Trials Is One Response To Placebo Concerns, Centocor Says
One response to concerns over the use of placebo therapy in rheumatoid arthritis trials is to exercise an "early escape" strategy, Centocor Executive Director-Immunology Clinical R&D Daniel Baker said
J&J's Remicade Adds Malignancy Warning To Labeling
New language on lymphoma in the Warnings and Adverse Reactions sections of labeling is substantially similar to that of other TNF-inhibitors – Amgen's Enbrel and Abbott's Humira. J&J is issuing a "Dear Doctor" letter to inform physicians of the changes.